EGFR and neoplasm: Figure 1e shows pathways with the highest contribution to the prediction of drug synergy of the Capivasertib + Sapitinib combination: these include the ERBB-related pathways (ERBB2 signaling pathway, ERBB pathway) and tumor-related pathways (lymph-node metastases, focal adhesion).